Eleven Therapeutics
Andrej Alendar has over 9 years of experience working as a Senior Scientist, including their current role as an Advanced Senior Scientist at Eleven Therapeutics since June 2023. Andrej previously worked as a Senior Scientist at Eleven Therapeutics from October 2021 to June 2023. Prior to their time at Eleven Therapeutics, Andrej worked as a Postdoc at Wellcome/CRUK Gurdon Institute from 2014 to 2021, where they studied RNA modifications and novel RNA methyltransferases. Before that, they were a Doctoral Student at The Netherlands Cancer Institute from 2002 to 2014, where they focused on characterizing the role of the chromatin remodeling protein CHD9 in development and lymphomagenesis.
From 1995 to 2002, Andrej Alendar attended the University of Belgrade, where they obtained a Master of Science degree in Molecular Biology and Physiology.
This person is not in any offices
Eleven Therapeutics
Eleven Therapeutics is a biotechnology company at the forefront of the artificial intelligence revolution in medicinal nucleic acids. The new generation of RNAi therapies is introduced by merging artificial intelligence, parallel functional testing, and combinatorial chemistry. SCSI-RNA is a programmable molecule that can be used to target anydisease or biological target of interest.